Stockscreener 앱 받기
13.26
4.92%
-0.69
Neuropace Inc 주식(NPCE)의 최신 뉴스
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - TipRanks
NeuroPace (NPCE) Loss Narrowing In Q4 Tests Bullish Profitability Narrative - simplywall.st
NeuroPace (NPCE) CMO sells shares under Rule 10b5-1 trading plan - Stock Titan
NeuroPace (NPCE) CEO reports 5,023-share tax-withholding disposition on RSU vesting - Stock Titan
Why NeuroPace Stock Was Inching Higher on Wednesday - AOL.com
Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool
NeuroPace (NPCE) Q4 2025 Earnings Call Transcript - The Globe and Mail
NeuroPace Q4 Earnings Call Highlights - MarketBeat
NeuroPace Beats Q1 Earnings Estimates - National Today
NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
Neuropace earnings beat by $0.10, revenue topped estimates - Investing.com Canada
NeuroPace : Investor Presentation - marketscreener.com
NeuroPace reports $99.99M revenue, $(0.66) EPS in 10-K - TradingView
NeuroPace Q4 Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
NeuroPace (NASDAQ:NPCE) Issues Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
NeuroPace (NPCE) outlines RNS growth, trials and capital moves in 10-K - Stock Titan
NeuroPace Inc.: Fourth Quarter Earnings Overview - Bitget
Neuropace Inc. (NPCE) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Press Release: NeuroPace Reports First Quarter 2025 Financial Results - 富途牛牛
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% - Investing.com South Africa
NeuroPace beats estimates as Q4 revenue surges 24%, sending shares up 15% By Investing.com - Investing.com Canada
NeuroPace Inc.: Q4 Earnings Snapshot - marketscreener.com
NeuroPace (NASDAQ: NPCE) posts 25% 2025 growth and sets 2026 revenue, margin guidance - Stock Titan
Earnings Summary: NeuroPace Q4 - Benzinga
NeuroPace, Inc. Reiterates Earnings Guidance for the first quarter and full year of 2026 - marketscreener.com
NPCE Earnings History & Surprises | EPS & Revenue Results | NEUROPACE INC (NASDAQ:NPCE) - ChartMill
NeuroPace (NPCE) CEO covers RSU taxes through 1,126-share withholding - Stock Titan
NeuroPace Inc RNS System reduces seizure frequency in epilepsy patient Brian - Traders Union
NeuroPace (NPCE) CMO has 358 shares withheld for RSU tax - Stock Titan
Earnings Outlook For NeuroPace - Benzinga
NeuroPace Inc (NPCE) Q4 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus
NPCE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Should You Buy Neuropace Inc (NPCE) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Neuropace Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Neuropace, Inc. (NPCE) Investor Outlook: Strong Buy Ratings and a 29.83% Upside Potential - DirectorsTalk Interviews
Earnings Preview: NeuroPace to Report Financial Results Post-market on March 03 - 富途牛牛
(NPCE) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
NeuroPace Q4: Has the Market Already Factored in the Results? - Bitget
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Finviz
NeuroPace (NPCE) Projected to Post Earnings on Tuesday - MarketBeat
NeuroPace (NPCE) CMO has shares withheld to cover RSU taxes - Stock Titan
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026 - Business Wire
Brain Implants Market to Reach USD 10.8 Billion by 2030 Growing - openPR.com
What’s the analyst consensus on NeuroPace Inc.Portfolio Update Report & Capital Efficient Trading Techniques - mfd.ru
How (NPCE) Movements Inform Risk Allocation Models - Stock Traders Daily
NPCE PE Ratio & Valuation, Is NPCE Overvalued - Intellectia AI
Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is NeuroPace Inc. stock a dividend growth opportunity2025 Retail Activity & Consistent Income Trade Recommendations - mfd.ru
Essex Investment Management Co. LLC Raises Holdings in NeuroPace, Inc. $NPCE - MarketBeat
How Does NeuroPace's Personalized Technology Transform Seizure Control - Kalkine Media
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Intraday: Is NeuroPace Inc a stock for growth or value investorsBond Market & High Conviction Buy Zone Alerts - baoquankhu1.vn
Neuropace, Inc. (NPCE) Stock Analysis: Exploring the 25.89% Potential Upside and Analyst Optimism - DirectorsTalk Interviews
Trading Systems Reacting to (NPCE) Volatility - Stock Traders Daily
How NeuroPace (NPCE) Analysts Are Quietly Rewriting The Story Behind The Stock - Yahoo Finance
NeuroPace stock price target raised to $20 from $19 at Leerink Partners By Investing.com - Investing.com Australia
NeuroPace stock price target raised to $20 from $19 at Leerink Partners - Investing.com Nigeria
1.94%
자본화:
|
볼륨(24시간):